|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||486.43 g/mol g·mol−1|
|3D model (JSmol)|
Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).
Vilanterol is available in following combinations:
- with inhaled corticosteroid fluticasone furoate—fluticasone furoate/vilanterol (trade names Breo Ellipta (U.S.), Relvar Ellipta (EU, RU, JPN))
- with muscarinic antagonist umeclidinium bromide—umeclidinium bromide/vilanterol (trade name Anoro Ellipta)
- with inhaled corticosteroid fluticasone furoate and muscarinic antagonist umeclidinium bromide—fluticasone furoate/umeclidinium bromide/vilanterol (trade name Trelegy Ellipta)
- Salmeterol—a long-acting β2 adrenoreceptor agonist (LABA) with a similar backbone.
- "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Retrieved 10 May 2013.
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|